Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nsaid + triptan
- Development stage
- Unknown
- Lead developer
- Apotex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of a **nonsteroidal anti-inflammatory drug (NSAID)** and a **triptan** is used mainly for the **acute treatment of migraine**. The most well-studied and widely approved example is the fixed-dose combination of **sumatriptan** (a triptan, serotonin 5-HT₁B/₁D agonist) and **naproxen sodium** (an NSAID that inhibits cyclooxygenase-1 and -2 enzymes, reducing prostaglandin synthesis and inflammation). This combination provides superior efficacy for achieving sustained pain freedom and relief compared to monotherapy with either agent, as each component targets distinct pathophysiological mechanisms in migraine: triptans act on the trigeminovascular system to induce vasoconstriction and block pain signal transmission, while NSAIDs reduce neurogenic inflammation in the trigeminal ganglion and prevent central sensitization. Typical indications are moderate to severe episodic migraine in adults.
- Brand names
- Treximet
- Other names
- sumatriptan + naproxentriptan + nsaidsumatriptan-naproxen
02
Targets
HTR1B (5-Hydroxytryptamine Receptor 1B)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)HTR1D (5-hydroxytryptamine receptor 1D)
Beyond the preview
Go deeper on nsaid + triptan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nsaid + triptan.